The Radcliffe Cardiology Podcast

In this Redcliffe Cardiology NVM reflections episode, Prof Nicolas Van Mieghem cuts through the noise from TCT 2025. Tune in to hear what the SELUTION trials mean for drug-coated balloons in de novo disease and ISR, why cost and sizing matter in calcium modification, how PE thrombectomy stacks up against anticoagulation alone, and what 7-year PARTNER 3 and 10-year NOBLE data signal for TAVR and left main PCI. Practical takeaways you can use on your next case. Drug-coated balloons (DCB): SELUTION-ISR and the large SOLUTION DeNovo RCT show non-inferiority vs contemporary care,with ~80% of DCB cases avoiding a stent. How to size, when to escalate to DES, and why 5-year data will be decisive. We also contrast these results with CAGE-FREE-1 three-year outcomes and discuss “not all DCBs are created equal.” Calcium strategies: SHORT-CUT and VICTORY pit cutting/high-pressure balloons against intravascular lithotripsy. Similar luminal results—but very different costs and workflow. We outline a toolbox and imaging-first algorithm for nodular/annular calcium and where atherectomy still fits. Pulmonary embolism: STORM-PE shows catheter thrombectomy on top of anticoagulation cuts RV/LV ratio fast along with real-world procedure times, blood loss, and complications you should counsel up front. Valves & MR: PARTNER 3 at 7 years TAVR vs surgery outcomes remain similar with reassuring valve durability; mild PVL not tied to mortality. ENCIRCLE (Sapien M3 TMVR) shows strong MR elimination but flags stroke and leaflet thrombosis prompting a rethink of antithrombotic strategy. Coronary trials: NOBLE 10-year left main results, PROCTOR (native CTO vs SVG PCI), I-MODERN (iFR-guided complete revasc vs deferred CMR), iCABG (physiology-guided grafting), INFINITY SWEDEHEART (bioadaptor stent signals), and ANDES (post-LAAO DOAC vs DAPT). Expect pragmatic thresholds, device selection tips, and critical review of the latest evidence with Prof Nicolas Van Mieghem.

At TCT 2025, Dr Nadira Hamid (Minneapolis Heart Institute, US) and Dr. Rahul P. Sharma (Stanford University, US) review the late-breaking trial data shaping the future of structural heart disease. The discussion highlights real-world results from TRISCEND and TRILUMINATE in tricuspid disease, 7-year PARTNER 3 durability outcomes in TAVR, national prevalence insights from the PREVUE-VALVE study, and new frontiers in mitral intervention with SUMMIT MAC. Together, they examine what the evidence means for safety, durability, patient selection, and clinical adoption. 01:05 – Tricuspid Therapies Late-breaking data from Triluminate (TriClip) and Tricend/Evoke: real-world outcomes, bleeding reduction, pacemaker trends, and patient selection. 06:40 – Aortic Valve Durability PARTNER 7-year outcomes: TAVR vs. SAVR, valve performance over time, implications for younger/lower-risk patients, and evolving device technology. 12:55 – Valvular Disease Prevalence Insights from the PREVUE-VALVE: first nationwide prevalence data, under-treatment of severe disease, and role of AI in early detection. 17:30 – Mitral Valve Advances Landmark trials: SUMMIT Trial (MAC population) and first-in-human Sapien M3 transseptal TMVR. Key outcomes, screen failure rates, and implications for clinical adoption. 24:50 – Future of Structural Heart Interventions Patient-first approach, expanding treatment options, and importance of durability and early diagnosis. For more content from TCT 2025 head to the Late-breaking Science Video Collection. Editor: Mirjam Boros Videographer: Tom Green and Dan Brent Support: This is an independent video produced by Radcliffe Cardiology.

Explore ESC 25 Top Trials with Insights from the Thoraxcenter! Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam, for an engaging and critical analysis of the latest trials unveiled at ESC 2025. In this comprehensive ESC wrap-up, interventional experts examine the most significant trials, providing valuable insights into their impact on current practices and future research directions. 00:15 - DOUBLE-CHOICE 04:43 - VANTAGE 07:44 - VICTOR and VICTORIA 11:29 - DIGIT-HF 14:22 - DAPA ACT HF-TIMI 68 16:55 - BETAMI-DANBLOCK and REBOOT-CNIC 22:13 - REFINE-ICD 25:34 - OPTION-STEMI 30:40 - DUAL-ACS 33:05 - NEO-MINDSET 35:58 - TARGET-FIRST 38:54 - OUTREACH 41:50 - FIRE 42:46 - AI-Gatekeeper 45:13 - POTCAST

Expert interventionalists, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) discuss the most anticipated hot line studies to be unveiled at ESC Congress 2025. Tune in for their in-depth analysis to get ahead of the curve. ESC Congress 2025 Hot Line Trials Discussed: 00:25 - DOUBLE-CHOICE 03:03 - VANTAGE 05:03 - VICTOR 06:28 - VICTORIA 07:58 - DIGIT HF 10:19 DAPA ACT HF-TIMI 68 12:35 REBOOT-CNIC 14:07 BETAMI DANBLOCK 16:03 REFINE ICD 18:05 OPTION STEMI 20:43 DUAL ACS 22:46 NEO MINDSET 24:53 TARGET FIRST 26:59 OUTREACH 29:29 FIRE 31:40 AI GATEKEEPER 22:42 LAA CLOSURE Stay tuned for Radcliffe Cardiology’s in-depth coverage of these and other pivotal trials from ESC Congress 2025.

Women in Cardiology: Small in Number, Large in Impact with Dr Roxana Mehran by The Radcliffe Cardiology Podcast

Explore the Top Trials from EuroPCR 25 with Insights from the Thoraxcenter! Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam, for an engaging and critical analysis of the latest trials unveiled at EuroPCR. In this comprehensive EuroPCR review, interventional experts examine the most significant trials, providing valuable insights into their impact on current practices and future research directions. 00:18 - UK TAVI 03:22 - ACURATE IDE 06:10 - COMPARE TAVI 07:21 - PROTECTED TAVR and BHF PROTECT TAVI Meta Analyses 11:51 - PROVISION 14:35 - REPEAT QFR 16:44 - FAITAVI 19:49 - ILIAS ANOCA 22:20 - CAREER 26:20 - RETRIEVE AMI 28:06 - ICARE-OFDI 32:28 - COMPARE-ABSORB 33:20 - BIOADAPTOR RCT 34:22 - PERFECT PSP 37:34 - bRIGHT 39:40 - TRINITY 41:45 - AMEND

What advice does Dr Ritu Thamman have for female cardiologists trying to navigate power dynamics within the workplace? Diversity, Inclusion and Equity in Cardiology hosts, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, Jeddah, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, London, UK) are joined by Dr Ritu Thamman (University of Pittsburgh School of Medicine, PA, US) to discuss the challenges posed by queen bee syndrome and the importance of building networks to feel secure in leadership positions. Together, they also explore how institutions can improve lab safety for interventional cardiologists and pregnant women at higher risk of radiation exposure, and Dr Thamman highlights the huge disparities between standards of protection across the globe. Finally, Dr Thamman offers valuable advice to younger colleagues struggling to create an attainable work-life balance.

What can the transition to industry offer young cardiologists, and should they take the leap? Diversity, Inclusion and Equity in Cardiology hosts, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, Jeddah, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, London, UK) engage in an inspiring discussion with Interventional Cardiologist, Dr Marta Bande (Boston Scientific Corporation, Milan, IT). The episode dives into Dr Bande's motivations to move to industry after years in clinical practise and the skills and opportunities this exposed her to. As well as providing advice for young cardiologists contemplating changing career paths, Dr Bande talks on navigating career struggles and why she actively promotes diversity for women within cardiology.

How can institutions overcome toxic workplace behaviours, and why is it important? Diversity, Inclusion and Equity in Cardiology hosts, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, Jeddah, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, London, UK) are joined by Prof Mamas Mamas (University of Keele, Staffordshire, UK) to discuss how we can achieve equity in the workplace. Together, they share insights on the dangers of tall poppy syndrome, how to recognise our biases, and why many feel unable to call out bullying and harassment. Prof Mamas also highlights the responsibility of institutions and leadership to implement a code of conduct, framework for independent reporting of uncivil behaviours, and implications if these are not met.

What is the reasoning behind the porosity of data when it comes to CV outcomes in women? Diversity, Inclusion and Equity in Cardiology hosts, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, Jeddah, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, London, UK) are joined by Prof Barbara Casadei (British Heart Foundation, University of Oxford, Oxford, UK) who offers her advice to young cardiologists who aren't receiving the recognition they deserve. As the first female president of the ESC, Prof Casadei discusses how to navigate challenges in leadership roles and her thoughts on recent society statements against toxic behaviours in the workplace. Lastly, she explores how to achieve gender equity in clinical trial research.

How can mentorship shape a career in cardiology, and what can we learn from a pioneer in the field? Join Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, UK) as they interview Professor Eugene Braunwald, Distinguished Hersey Professor of Medicine at Harvard Medical School. Prof Braunwald shares his experiences with mentorship, including how it facilitated his research and influenced his career. He also discusses mentorship experiences of Dr Nina Starr Braunwald, the first female cardiac surgeon, highlighting the impact of mentorship and determination in overcoming discrimination. Prof Braunwald provides invaluable career advice for young cardiologists, emphasizing the need for focused research. The episode also explores his predictions for the field of cardiology over the next 20 years, which includes a significant push for preventative measures and potential advances in xenotransplantation and device technology.

Introducing our new podcast series, Diversity, Inclusion and Equity in Cardiology with hosts, Dr Mirvat Alasnag and Dr Julia Grapsa. Starting with Prof Braunwald, this series features expert guests who discuss topics from navigating challenging work environments to the future legacy for women in cardiology.

This episode examines the multidisciplinary team (MDT) in HCM, exploring its ideal structure, function, and real-world challenges. Prof Juan Pablo Kaski is joined by Dr Elena Biagini and Dr Jodie Ingles to share insights from their work on the 2023 ESC guidelines and MDT care.

In this exclusive episode of the "Innovations in Cardiology" podcast series, host Dr Dipti Itchhaporia, past president of the American College of Cardiology, delves into the latest advancements in cardiovascular health. She is joined by Dr Valentin Fuster, a pioneer in the field, who shares invaluable insights into the impact of biological ageing, the connection between the heart and brain, and the role of artificial intelligence in healthcare. Dr Fuster challenges the traditional focus on chronological age, highlighting the significance of biological age as a more accurate predictor of cardiovascular risk. Together, he and Dr Itchhaporia explore innovative ways to measure biological age and discuss the factors that influence it. The conversation then shifts to the importance of early intervention in cardiovascular disease, with Dr Fuster advocating for screening in younger individuals. They also discuss the transformative potential of polypills in preventing and treating heart disease, weighing the benefits against challenges such as adherence and cost-effectiveness. As the episode wraps up, Dr Fuster offers his predictions for the future of cardiovascular care and shares valuable advice for those just beginning their careers in the field. If you have any questions or suggestions for topics to cover on the Radcliffe Podcast, please email [email protected].

Join interventional cardiologists, Prof Nicolas Van Mieghem and Dr Joost Daemen from the Thoraxcenter as they unpack the most impactful late-breaking clinical trials and science data from this year's Transcatheter Cardiovascular Therapeutics Conference. Dive into this practical and engaging discussion and learn more about the latest data for practice and for research. Trials covered in detail include: ECLIPSE (00:49 - 05:55) FAVOR III (05:55 - 10:30) FLASH (10:30 - 12:54) DCB BIFURCATION (12:54 - 15:17) EARLY TAVR (15:17 - 21:14) EVOLVED (21:14 - 24:07) TAVR-UNLOAD (24:07 - 28:57) PEERLESS (28:57 - 31:14) CLEAR IE (31:14 - 33:29) TRISCEND II (33:29 - 36:36) ACCESS TAVI (36:36 - 40:05) ALIGN AR (40:05 - 41:49) COSTAR RCT (41:49 - 43:36) ACURATE IDE (43:36 - 46:42) CLEAR SYNERGY(46:42 - 48:41) This is an independent interview produced by Radcliffe Cardiology.

In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, Newport Beach, CA, US) is joined by Dr Alexander Van Rosendael (Leiden University Medical Center, Leiden, NL) to discuss the findings from the CONFIRM2 trial. Conducted from up to 50 international clinical CCTA sites with 35,000 patients, CONFIRM2 aims to improve comprehensive quantification of coronary computed tomography angiography findings using an artificial intelligence algorithm that will enable an accurate quantification of coronary artery disease, including total coronary plaque volume and low attenuation plaque volume. Findings showed that AI-guided quantative computational tomography quantification of coronary CTA lumen diameter stenosis and the noncalcified plaque volume were most predictive of MACE and added discriminative accuracy to the Diamond and Forrester predictive model. These atherosclerotic profiles as assessed by AI-QCT could guide the tailoring of anti atherosclerotic therapies or coronary interventional procedures to reduce the instance of cardiac events. If you have any questions or suggestions for topics to cover on the Radcliffe Podcast, please email [email protected].

Explore the cardiovascular breakthroughs shaping AHA 2024! Join renowned experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) as they preview the most impactful late-breaking studies poised to make waves at this year’s AHA Conference. Dive into their expert analysis and gain key insights into the studies that are set to drive the future of cardiovascular care. Trials discussed in detail include: CLEAR-SYNERGY (01:01 - 03:45) SELECT (03:45 - 04:47) SUMMIT (04:47 - 08:28) YELLOW III (08:28 - 11:05) AMULET IDE (11:05 - 12:25) VALOR-HCM (12:25 - 13:39) Stay tuned for Radcliffe Cardiology's in-depth coverage of these and other pivotal trials from AHA Conference 2024.

In this episode of the "Innovations in Cardiology" series, host Dr. Dipti Itchhaporia, former president of the ACC, is joined by Dr. C. Michael Gibson, CEO of the Baim Institute for Research, for an insightful discussion on the latest advancements and future directions in cardiovascular innovation for 2024. Dr. Itchhaporia and Dr. Gibson explore strategies to enhance efficiency in cardiovascular research, with a focus on direct-to-patient trials. They delve into how this approach can be optimized to better target patients and improve outcomes. Dr. Gibson shares details about a groundbreaking platform being developed to support long-term follow-up studies, enabling patient monitoring for up to 20 years through persistent follow-up alerts. The conversation also touches on key findings from the Apple Heart Study, particularly in relation to atrial fibrillation detection via the Apple Watch, and the differences in compliance rates between older and younger patients. Additionally, they discuss the upcoming results of the Heartline Study, which focuses on patients aged 65 and older. Looking ahead, Dr. Itchhaporia and Dr. Gibson reflect on the future of cardiovascular care, including the potential for personalized care plans tailored to each patient. They consider the timeline for integrating this approach into clinical practice, potential barriers to implementation, and the significant opportunities it presents for improving patient outcomes. If you have any questions or suggestions for topics to cover on the Radcliffe Podcast, please email [email protected].

Host, Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, Newport Beach, CA, US) is joined by PI, Dr Derek Chew (Monash Heart and Victorian Heart Institute, AU) to discuss the findings from the RAPIDxAI trial, which aims to improve the assessment of suspected cardiac chest pain in emergency departments (ED) using a machine-learning algorithm that will interpret high-sensitivity troponin test results, assisting the diagnosis of myocardial infarction (MI) and other myocardial injuries. Conducted across 12 hospitals with 9600 patients, RAPIDxAI compares AI-supported decision-making to standard of care. Investigators found that the availability of AI-based decision making tools guiding diagnostic and prognostic evaluation of high-sensitivity troponin T did not impact clinical care to improve cardiovascular outcomes. There was no increased risk using the algorithms observed in the trial, demonstrating the safety of the algorithm. Dr Itchhaporia and Dr Chew discuss the trust levels of cardiologists in implementing AI algorithms into clinical practice, and cost-effective methods of validating AI, as well as the lessons learnt from the trial. If you have any questions or suggestions for topics to cover on the Radcliffe Podcast, please email [email protected].

In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia welcomes two leading experts in artificial intelligence in cardiology: Dr David Ouyang from Cedars-Sinai Medical Center in Los Angeles, and Dr Francisco Lopez-Jiminez from the Mayo Clinic in Rochester, MN. Together, they explore the role of artificial intelligence in cardiology, from diagnostics to personalized treatment strategies. Dr. Lopez-Jiminez shares insights from the AI-ECG study, delving into its clinical reception and the potential for scaling these findings across various healthcare settings. Dr. Ouyang addresses the challenges of integrating AI into clinical practice, highlighting the areas where rapid advancements are occurring. Both experts offer valuable advice to clinicians who would like to stay abreast of AI trends in healthcare, and engage in debate on whether AI will ultimately revolutionize clinical care, including the timelines for these anticipated changes. If you have any questions or suggestions for topics to cover on the Radcliffe Podcast, please email [email protected].

What's hot at ESC Congress 2024? Join us for a comprehensive analysis of the most impactful hot line trials presented at the European Society of Cardiology (ESC) Congress 2024. In the latest episode of the View from the Thoraxcenter, Prof Nicolas van Mieghem and Dr Joost Daemen (Thoraxcenter at Erasmus MC, NL) provides an overview of the new findings and their implications for clinical practice. What should we consider when interpreting hotline data from ESC 24? How will these trials impact future research? What questions should we ask before applying the new data to clinical practice? Trials in detail covered: 00:37 RESHAPE-HF2 06:11 MATTERHORN 11:01 Tri.fr 14:43 SWEDEGRAFT 17:46 OCCUPI 22:59 REC-CAGEFREE I 28:10 SENIOR-RITA 32:58 EARTH-STEMI 35:23 POPular PAUSE TAVI 38:31 NOTION-3 44:32 RHEIA Support: This is an independent interview produced by Radcliffe Cardiology.

This episode features a comparative summary of international guidelines, highlighting key differences and assessing the adequacy of current recommendations. The discussion also identifies gaps in existing clinical evidence, providing insights into what is currently missing in HCM research.

In this episode, Prof Juan Pablo Kaski is joined by Dr Carolyn Ho, join them in this 20-minute discussion on essential management topics, including phenotyping, triaging, symptomatic care, and transplant considerations.

In this episode, Prof Juan Pablo Kaski is joined by Dr Jodie Ingles and Dr Elena Biagini to discuss long-term management, expectations in cardiology, community care and family genetic screening. Tune in for expert insights on supporting patients and their families.

What's hot at EuroPCR 2024? Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC's Thoraxcenter for an insightful preview of the late-breaking science data to look out for at the 2024 EuroPCR meeting. What is the potential impact of the new data on practice? What details should we look out for? What is the context of the EuroPCR trials? Trials covered included: 00:46 - CAREER 02:03 - Angiography-based Radial Wall Strain in Predicting Non-Culprit Vessel Failure 04:05 - DOCTORS-LM 07:41 - TCW 09:35 - SOLVE-TAVI 12:27 - NOTION-2 14:41 - LANDMARK 16:36 - AltaValve 17:53 - LuxValvePlus 19:12 - CALIPSO 21:44 - ROTA-ISR 23:57 - ROLLERCOASTR 25:20 - Balloon Angioplasty Vs Shockwave Intravascular Lithotripsy 25:29 - OCT Vs IVUS

In the first episode, Prof Juan Pablo Kaski and Prof Ruxandra Jurcut discuss the essentials of establishing an HCM Clinic, covering its objectives, logistical aspects, systemic challenges, and operational strategies, including referral practices and collaboration with specialist centres.

Unpack ACC.24's Top Trials with View from the Thoraxcenter! Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam for a deep dive into the late-breaking data presented at ACC.24. In this thought-provoking ACC 2024 wrap-up, delve into the nuances of the most impactful trials, gaining insights into their implications for current practice and future research directions. 00:29 - Ultimate DAPT 02:49 - IVUS-ACS 04:22 - RELIEVE-HF 08:00 - ORBITA-COSMIC 11:12 - EMPACT-MI 14:36 - REDUCE-AMI 17:51 - DEDICATE-DZHK6 22:32 - SMART 26:26 - PREVENT 29:08 - FULL REVASC 33:43 - DanGer Shock 39:44 - TARGET BP I

In this episode of the Radcliffe Podcast, we are joined by Dr Raymond Pranata, Dr Mohammad Iqbal and Dr Giky Karwiky (Hasan Sadikin General Hospital, Bandung, Indonesia) as they discuss their recently published systematic review and meta-analysis of very-high-power short-duration ablation as compared to conventional ablation for the treatment of pulmonary vein isolation in atrial fibrillation. 13 studies were included in their analysis, which found that VHPSD ablation was associated with lower AF recurrence as compared to the conventional ablation group. Subgroup analysis showed that additional ablation beyond PVI had a similar rate of AF recurrence compared to PVI alone. If you have any questions or suggestions, please email [email protected].

What's hot at #AHA23? Join Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) as they review the latest late-breaking science data from AHA Scientific Sessions 2023. They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research. Trials Covered include: 00:20 - DAPA-MI: Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack 06:30 - ORBITA-2: Percutaneous Coronary Intervention for Stable Angina: A Randomised, Placebo-Controlled Trial 12:39 - A Sub-Analysis of the Prospective ECLS-Shock Trial 16:13 - ARTESiA: Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation 10:02 - SELECT: Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity Who Do Not Have Diabetes We value your opinion! Share your feedback by commenting on this page or sending us an email at [email protected].

What are the top late-breaking trials from #TCT2023? TCT 2023 — Join interventional cardiologists, Prof Nicolas Van Mieghem and Dr Joost Daemen from the Thoraxcenter as they unpack the most impactful late-breaking clinical trials and science data from this year's Transcatheter Cardiovascular Therapeutics Conference. Dive into this practical and engaging discussion and learn more about the latest data for practice and for research. We value your opinion! Share your feedback by commenting on this page or sending us an email at [email protected]. Trials covered: 00:20 - PARTNER 3 Low-Risk: Five-Year Clinical and Echocardiographic Outcomes 01:47 - EVOLUT Low-Risk: Four-Year Outcomes From the EVOLUT Low Risk Trial 04:02 - ALIGN-AR: Initial Outcomes of the JenaValve Trilogy Transcatheter Aortic Valve Replacement 06:18 - VIVA: Transcatheter versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Small Aortic Annuli 08:19 - AGENT IDE: Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT 11:56 - DCB-ACS: Drug-Coated Balloon for Acute Coronary Syndromes 14:06 - T-PASS: Less Than 1-month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy after Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome 16:40 - WATCH TAVR: Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve 19:20 - TRILUMINATE: Quality of Life After Transcatheter Tricuspid-Valve Repair vs. Medical Therapy in Patients with Severe Tricuspid Regurgitation 21:13 - TRISCEND II: A Randomized Trial of Transcatheter Tricuspid Valve Replacement in Patients With Severe Tricuspid Regurgitation 23:23 - PICSO-AMI-I: Pressure-Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction 26:07 - RADIANCE: Individual Patient-data Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure at 6 Months

What are the take-home messages from ESC 2O23? Join us as we delve into the pivotal results that ignited debates and discussions at ESC Congress 2023. Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) return with their "View from the Thoraxcenter" review, where they analyse the hot line and late-breaking trials presented in Amsterdam. In this ESC 2023 wrap-up, Prof Van Mieghem and Dr Daemen will dissect the data, evaluating real-world applicability, and distilling findings into actionable insights for clinical practice.

What is hot at ESC 2023? In this episode of View of the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, NL) preview the hot line and late-breaking data presented at ESC Congress 2023. With their dynamic analysis, they place these highly anticipated trials within a context, highlighting the real-world implications tied to the data releases. Top trials covered 00:31: ECLS-SHOCK: Extracorporeal life support in cardiogenic shock 03:25: EARLY-UNLOAD: Early left ventricular unloading after extracorporeal membrane oxygenation 05:21: ARREST: Expedited transfer to a cardiac arrest center for OHCA 07:33: GUIDE-DES: QCA versus IVUS guidance for DES implantation 10:38: ILUMIEN IV: OCT versus angiography 13:11: OCTOBER: OCT-guided or angiography-guided PCI in complex bifurcation lesions 16:14: OCTIVUS: OCT- versus IVUS-guided PCI 18:27: FIRE: Functional versus culprit-only revascularization in elderly patients with myocardial Infarction and multivessel disease 19:50: OCT vs IVUS vs Angiography Guidance 20:11: Meta-analysis of iFR-SWEDEHEART and DEFINE FLAIR 20:53: HEART-FID: Ferric carboxymaltose in heart failure with iron deficiency 22:14: STOPDAPT-3: An aspirin-free antithrombotic strategy for percutaneous coronary intervention 24:50: MULTISTARTS AMI: Multivessel immediate versus staged revascularization in STEMI 26:20: NOTION: The nordic aortic valve intervention trial Mark your calendar for our ESC Congress coverage starting August 25. Interviews, discussions and insights live from Amsterdam.

In this episode of the Radcliffe Podcast, we are joined by Dr Mirvat Alasnag (King Fahd Armed Forces Hospital, SA), Dr Khalid AlJohani (King Saud University, SA), and Dr Abdulrahman AlMoghairi (Prince Sultan Cardiac Center, SA) as they discuss methods and approaches to left main percutaneous coronary revascularization. In this podcast, Dr Alasnag, Dr AlJohani and Dr AlMoghairi discuss the current guidelines for left main PCI, the techniques they use to position and optimise left main ostial stents, and intracoronary imaging to assist stent placement in the left main artery. They also discuss recent research into left main PCI, including the conflicting results of the EBC Main and DK Crush V trials. Dr AlMoghairi then outlines his thoughts towards mechanical circulatory support in left main stenting. Finally, Dr Alasnag, Dr AlJohani and Dr AlMoghairi discuss the gaps in knowledge and opportunities for future research, including operator training and geographic differences in left main PCI. What are the latest developments in left main percutaneous coronary intervention? Where are the knowledge gaps? Prefer to watch in video format? Click here. If you have any questions or suggestions, please email [email protected].

Join Masterclass host, Dr. Harriette Van Spall (McMaster University, CA), in an in-depth interview with Dr. Clyde W. Yancy (Northwestern University, US). Dr. Yancy, an internationally respected leader and mentor in cardiology, holds positions as the Vice Dean of Diversity and Inclusion, Magerstadt Professor of Medicine, and Chief of the Division of Cardiology at Northwestern University's Feinberg School of Medicine. He is also the Associate Director at the Bluhm Cardiovascular Institute Northwestern Memorial Hospital and a Deputy Editor of JAMA Cardiology. Discover Dr. Clyde W. Yancy's extraordinary journey as he shares invaluable insights from his professional and personal experiences. Uncover the pivotal moments that shaped his path and learn how he transformed obstacles into opportunities. Gain perspectives on the concept of servant leadership and delve into Dr. Yancy's thoughts on parenthood. In this enlightening interview's culmination, Dr. Yancy imparts his most crucial lesson and offers valuable tips tailored for institutional leaders.

In this episode from the Radcliffe Podcast, Dr Francisco Lopez-Jimenez (Mayo Clinic, US) and Dr David Harmon (Mayo Clinic, US) join us to discuss the future of AI in Atrial Fibrillation treatment, based on Dr Harmon's recently published article in AER Journal; 'Artificial intelligence for the detection and treatment of atrial fibrillation'. Dr Lopez-Jimenez and Dr Harmon discuss the possibilities that recent advances in the detection of atrial fibrillation using artificial intelligence-based technology offer, discussing its place in practice with consideration to standard practice electrocardiograms and advanced Holter ECG monitoring. They go on to discuss the implementation of this technology in day-to-day practice, as well as the potential barriers that may impact this. How could Artificial Intelligence impact your practice, and what are the recent advances? Prefer to watch in video format? https://www.aerjournal.com/video-index/artificial-intelligence-atrial-fibrillation If you have any questions or suggestions, please email [email protected].

In this episode of the Radcliffe Cardiology Podcast, we are joined by Dr Jack Tan (National Heart Centre, SG) and Dr Chris Plummer (The Newcastle upon Tyne Hospitals NHS Foundation Trust, UK), who provide an overview of a recent JAPSC Journal article based on the European Examination in Core Cardiology. The test aims to provide a broad and balanced evaluation of the key knowledge required by cardiology speciality trainees. Dr Plummer outlines the main components of the test, as well as the methods used to determine the questions used within the examination. Prefer to watch in video format? Click here. If you have any questions or suggestions, please email [email protected].

In this episode of "View from the Thoraxcenter," Prof Nicolas Van Mieghem and Dr Joost Daemen preview the most anticipated late-breaking and featured science trials of ACC.23 and discuss their potential impact on patient care and research. The trials covered include structural interventions such as TRILUMINATE Pivotal, UK Mini Mitral, COAPT, and Evolut Low Risk, as well as coronary interventions including REVIVED-BCIS2, RENOVATE-COMPLEX-PCI, and BIOVASC. Additionally, they cover trials related to statins, including Yellow III, CLEAR Outcomes, and MK-0616. Tune in for the latest developments in cardiology research.

In this episode of the Radcliffe Cardiology Podcast, Dr Otilia Tica (University of Birmingham, UK) is joined by Patient Representative, Mary Stanbury to outline ways in which cardiologists can break the cycle of heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF). This discussion is centered around a recently published article authored by Dr Tica in CFR Journal, 'Breaking the Cycle of Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation'. [https://www.cfrjournal.com/articles/breaking-cycle-heart-failure-preserved-ejection-fraction-and-atrial-fibrillation] In this episode, key discussion topics include: - Diagnosis, treatment and patient wellbeing for comorbid HFpEF and AF - Adverse event rates and prognostic implications for HFpEF and AF, and how we can close the gaps in the diagnostic challenges - Approaches and critical steps to patient management Prefer to watch in video format? Click here. If you have any questions or suggestions, please email [email protected].

In the third part of ECR Podcast's series on sex-differences in hypertension, Dr Isabella Sudano (University Hospital and University of Zurich, Zurich, CH) and Dr Eva Gerdts (Haukeland University Hospital, Bergen, NO) are joined by Prof Renata Cifkova (Institute of Experimental Medicine, Prague, CZ) to discuss the diagnosis of hypertension in women, including how we can raise awareness for this issue. Discussion points include: What are the main challenges for early diagnosis today? Current ESC/ESH guidelines recommends regular measurement of BP in all adults >18 years. To what extent is this followed up in European countries? Are there any particular groups that need more careful follow-up of BP? Healthy young and middle-aged women have much lower BP than men at the same age. Recent publications have demonstrated that CVD risk increases at a lower level in women than in men. Do you think we need sex specific thresholds for diagnosis of hypertension? What about role of adherence and persistence in blood pressure control? Are there known sex-differences? What are the underlying reasons for less control in women compared to men at the same age? Prefer to watch in video format? Click here. If you have any questions or suggestions, please email [email protected].

In the second part of ECR Podcast's series on sex-differences in hypertension, Dr Isabella Sudano (University Hospital and University of Zurich, Zurich, CH) and Dr Eva Gerdts (Haukeland University Hospital, Bergen, NO) are joined by Dr Angela Maas (Radboud University Medical Center, Nijmegen, NL) to talk about the cardiovascular complications that may arise in women as a result of hypertension. Discussion points include: What do we know about sex differences in risk factors for coronary artery disease? Traditional risk factors better identify risk for type 1 myocardial infarction, i.e. myocardial infarction due to coronary artery stenosis. What are the most important risk factors for type 2 myocardial infarction? Myocardial infarction is increasing among young women in several countries. What are the important underlying factors for this observation? What about sex-differences in echocardiographic changes in hypertension and regression of hypertensive heart disease? In women, hypertension, diabetes, obesity and smoking are more potent risk factors than in men for heart failure. Why is it so? How can we reduce cardiovascular complications in women with hypertension? Prefer to watch in video format? Click here. If you have any questions or suggestions, please email [email protected].

In the first of a three-part ECR Podcast series on hypertension in women, Dr Isabella Sudano (University Hospital and University of Zurich, Zurich, CH) and Dr Eva Gerdts (Haukeland University Hospital, Bergen, NO) are joined by Prof Juan Tamargo (University Complutense, Madrid, ES) to discuss pharmalogical treatment options and considerations. Discussion points for this episode include: Are there differences in the effect of antihypertensive treatment between women and men? Why do women more often report adverse events of diuretics, beta-blockers, CCB, and ACEi? Swedish registries have reported differences in prescriptions for women and men with hypertension. Women are more often prescribed diuretics, and men are more often ACEI. Is there a rationale for this? Sex-specific analysis of drug effects has only been reported in a few clinical trials. Are such analyses important and what is the knowledge today? Should we consider choosing the dose of antihypertensive drugs according to sex? If you have any questions or suggestions, please email [email protected].

What considerations must be made when screening chronic total occlusion patients undergoing PCI, and how can CT be used in daily practice? In this month's episode of ECR Podcast, Dr Vinoda Sharma, (Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK) and Dr Abdul Mozid, (Leeds Teaching Hospitals NHS Trust, Leeds, UK) discuss the ways in which CT coronary angiography can be utilised in chronic total occlusion percutaneous coronary interventions, and how the procedures differ across their UK-based practices. Prefer to watch in video format? Click here. If you have any questions or suggestions, please email [email protected].

What are the social factors that impact access to coronary and structural intervention in the current landscape of cardiology? In this month's episode of ECR Podcast, guest editor of ECR's special focus on gender disparities in interventional and structural heart procedures, Dr Natalia Berry (Mid Atlantic Permanente Medical Group, Washington DC, USA) is joined by Dr Renee Bullock-Palmer, (Deborah Heart and Lung Center, Pemberton, NJ, USA) to answer some of these questions. If you have any questions or suggestions, please email [email protected].

What are the clinical challenges in the use of biomarkers to estimate the risk of a cardiovascular event? Join Dr Bruna Gigante (Karolinska Institute, Solna, SE) in a discussion of potential biomarkers which may impact a patient’s cardiovascular risk profile. In this month’s featured author episode of the ECR Podcast, Dr Gigante discusses novel biomarkers and the clinical challenges which may be faced when estimating a patient’s cardiovascular risk.

Join Prof Juan Carlos Kaski (St George’s University of London, UK) and Dr Aernoud Fiolet (University Medical Center Utrecht, Netherlands) as they explore topics such as how guidelines currently view anti-inflammatory approaches and main molecules under investigation. Supported by an unrestricted educational grant from NOVO NORDISK A/S.

Prof Juan Carlos Kaski (St George’s University of London, UK) alongside Dr Peter Libby (Brigham and Women’s Hospital, Boston, US) provide us with a short and concise discussion regarding Therapeutic Targets and Mode of Action. Supported by an unrestricted educational grant from NOVO NORDISK A/S.

Inflammation and Atherosclerosis – What is the Link with CKD? Join Prof Juan Carlos Kaski (St George’s University of London, UK) and Prof Lina Badimon (Hospital of Santa Creu and San Pau, Barcelona, Spain) as they discuss that very question. Supported by an unrestricted educational grant from NOVO NORDISK A/S.

Inflammatory Signalling in Atherosclerosis and CKD is the topic of interest in this short peer to peer discussion involving Prof Juan Carlos Kaski (St George’s University of London, UK) and Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US). Supported by an unrestricted educational grant from NOVO NORDISK A/S.

Prof Juan Carlos Kaski (St George’s University of London, UK) is joined by Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US) to discuss Unmet Clinical Needs in Atherosclerosis and Chronic Kidney Disease where they cover topics such as elevated hsCRP and chronic kidney disease. Supported by an unrestricted educational grant from NOVO NORDISK A/S.

Prof Jean-Claude Tardif (Montreal Heart Institute, Canada) gives us a comprehensive overview of the COLCOT trial. Supported by an unrestricted educational grant from NOVO NORDISK A/S.